BioSyent Inc. (CVE:RX – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday. The stock traded as high as C$18.40 and last traded at C$17.99, with a volume of 9,231 shares changing hands. The stock had previously closed at C$18.10.
BioSyent Trading Down 0.2%
The business’s fifty day moving average is C$16.88 and its 200-day moving average is C$15.28. The firm has a market cap of C$196.00 million, a P/E ratio of 20.43 and a beta of 1.08. The company has a debt-to-equity ratio of 6.52, a quick ratio of 6.91 and a current ratio of 1.99.
Insider Transactions at BioSyent
In other news, Director Seyed Ahmad Ashrafi sold 2,900 shares of the firm’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of C$16.55, for a total transaction of C$47,995.00. Following the completion of the transaction, the director owned 21,461 shares of the company’s stock, valued at approximately C$355,179.55. This trade represents a 11.90% decrease in their ownership of the stock. In the last ninety days, insiders have sold 7,251 shares of company stock valued at $118,207. Corporate insiders own 33.65% of the company’s stock.
About BioSyent
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
See Also
- Five stocks we like better than BioSyent
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.
